Latest market price
22.72
+0.19+0.84%
Earnings
Up 0.8% — Earnings due 2026-11-03 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.85 | Insider Own | 42.68% | Shs Outstand | 168.61M | Perf Week | -2.66% |
| Market Cap | 3.83B | Forward P/E | — | EPS next Y | -1.68 | Insider Trans | -0.20% | Shs Float | 120.67M | Perf Month | -7.08% |
| Enterprise Value | 2.85B | PEG | — | EPS next Q | -0.35 | Short Float | 37.11% | Perf Quarter | -16.50% | ||
| Income | -124.00M | P/S | 70.94 | EPS this Y | — | Short Ratio | 16.08 | Perf Half Y | 8.29% | ||
| Sales | 54.00M | P/B | 3.74 | EPS next Y | — | ROA | -11.52% | Short Interest | 44.78M | Perf YTD | 156.43% |
| Book/sh | 6.08 | P/C | 3.78 | EPS next 5Y | — | ROE | -25.74% | 52W High | 34.39 -33.93% | Perf Year | 190.17% |
| Cash/sh | 6.01 | P/FCF | — | EPS past 3/5Y | — | ROIC | -12.90% | 52W Low | 7.37 208.28% | Perf 3Y | 208.70% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 35.36% 50.61% | Gross Margin | 98.25% | Volatility | 6.60% 7.19% | Perf 5Y | 72.38% |
| Dividend TTM | — | EV/Sales | 52.76 | EPS Y/Y TTM | — | Oper. Margin | -253.38% | ATR (14) | 1.80 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 50.82 | Sales Y/Y TTM | 125.00% | Profit Margin | -229.92% | RSI (14) | 46.69 | Recom | 2.08 |
| Dividend Gr. 3/5Y | — | Current Ratio | 50.82 | EPS Q/Q | -5.71% | SMA20 | -2.51% | Beta | 1.21 | Target Price | 47.27 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | -100.00% | SMA50 | -3.75% | Rel Volume | 1.60 | Prev Close | 22.53 |
| Employees | 137 | LT Debt/Eq | 0.03 | Earnings | Nov 03 | SMA200 | 1.75% | Avg Volume | 3.29M | Price | 22.72 |
| IPO Date | Sep 03, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -16.64% — | Net Debt/EBITDA | — | Volume | 5,279,085 | Change | 0.84% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-26 | Reiterated | Stifel Nicolaus | $40 → $55 | |
| Aug-18-26 | Reiterated | HC Wainwright & Co. | Buy | $66 → $68 |
| Aug-12-26 | Reiterated | Guggenheim | Buy | $12 → $35 |
| Jul-17-26 | Reiterated | Mizuho | Outperform | $36 → $40 |
| Jun-29-26 | Reiterated | Canaccord Genuity | Buy | $42 → $46 |
| Jun-26-26 | Upgrade | Jefferies | Hold → Buy | $60 |
| Jun-09-26 | Reiterated | Canaccord Genuity | Buy | $42 |
| Jun-09-26 | Reiterated | HC Wainwright & Co. | Buy | $13 → $66 |
| Jun-08-26 | Reiterated | Mizuho Securities | Outperform | $30 → $36 |
| Jun-08-26 | Reiterated | Wolfe Research | $35 |
Latest News· Times ET
Oct-30-26
Oct-30-2607:08AM
Oct-28-26
Oct-28-2604:15PM
Oct-27-26
Oct-27-2609:01AM
Oct-26-26
Oct-23-26
Oct-23-2604:57PM
12:06PM
11:36AM
06:30AM
06:30AM
Oct-16-26
Oct-16-2607:00AM
Oct-06-26
Oct-06-2603:17AM
Sep-23-26
Sep-23-2605:09AM
Sep-18-26
Sep-18-2604:09AM
Sep-10-26
Company
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 54 | 62 | 42 | 37 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 2 | 0 | 0 | — | — | — | — | |
| Gross Profit | 54 | 60 | 42 | 37 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 57 | 42 | 44 | 36 | — | — | — | — | |
| Research and Development | 134 | 132 | 144 | 115 | — | — | — | — | |
| Other Operating Expense | -2 | -3 | 0 | 0 | — | — | — | — | |
| Operating Income | -137 | -111 | -146 | -114 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 10 | 16 | 13 | — | — | — | — | |
| Net Income Before Taxes | -124 | -102 | -130 | -102 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -124 | -102 | -130 | -102 | — | — | — | — | |
| Net Income From Continuing Operations | -124 | -102 | -130 | -102 | — | — | — | — | |
| Net Income | -124 | -102 | -130 | -102 | — | — | — | — | |
| EPS (Recurring) | -0.85 | -0.87 | -1.19 | -1.08 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.85 | -0.87 | -1.19 | -1.08 | — | — | — | — | |
| EPS (Diluted) | -0.85 | -0.87 | -1.19 | -1.08 | — | — | — | — | |
| EBITDA | -122 | -99 | -128 | -99 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 63.11 | 16.58 | 8.02 | 25.42 | — | — | — | — | |
| Gross Margin | 100.00 | 96.77 | 100.00 | 100.00 | — | — | — | — | |
| Operating Margin | -253.70 | -179.03 | -347.62 | -308.11 | — | — | — | — | |
| Net Margin | -229.63 | -164.52 | -309.52 | -275.68 | — | — | — | — | |
| Shares Outstanding | 150 | 116 | 109 | 95 | — | — | — | — | |
| Market Capitalization | 3,408 | 1,028 | 337 | 941 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D | Oct 01 '26 | Sale | 24.47 | 27,000 | 660,796 | 115,743 | Oct 05 |
| Crystal Adam | President, R&D | Oct 01 '26 | Option Exercise | 5.20 | 27,000 | 140,400 | 142,743 | Oct 05 |
| Newcomb Jessica | Principal Accounting Officer | Sep 22 '26 | Sale | 24.22 | 8,200 | 198,612 | 59,121 | Sep 24 |
| Crystal Adam | President, R&D | Sep 01 '26 | Option Exercise | 5.20 | 27,000 | 140,400 | 142,743 | Sep 03 |
| Crystal Adam | President, R&D | Sep 01 '26 | Sale | 22.37 | 27,000 | 603,909 | 115,743 | Sep 03 |
| Crystal Adam | President, R&D | Aug 03 '26 | Option Exercise | 5.20 | 27,000 | 140,400 | 142,743 | Aug 05 |
| Crystal Adam | President, R&D | Aug 03 '26 | Sale | 27.24 | 27,000 | 735,517 | 115,743 | Aug 05 |
| Crystal Adam | President, R&D | Jul 01 '26 | Option Exercise | 5.20 | 27,000 | 140,400 | 142,743 | Jul 02 |
| Crystal Adam | President, R&D | Jul 01 '26 | Sale | 29.59 | 27,000 | 798,908 | 115,743 | Jul 02 |
| Crystal Adam | President, R&D | Jun 01 '26 | Option Exercise | 5.20 | 27,000 | 140,400 | 142,743 | Jun 03 |
| Crystal Adam | President, R&D | Jun 01 '26 | Sale | 22.87 | 27,000 | 617,571 | 115,743 | Jun 03 |
| Crystal Adam | President, R&D | May 01 '26 | Option Exercise | 5.20 | 27,000 | 140,400 | 142,743 | May 05 |
| Crystal Adam | President, R&D | May 01 '26 | Sale | 21.23 | 27,000 | 573,097 | 115,743 | May 05 |
| Crystal Adam | President, R&D | Apr 15 '26 | Option Exercise | 5.20 | 38,460 | 199,992 | 151,082 | Apr 16 |
| Crystal Adam | President, R&D | Apr 15 '26 | Sale | 25.00 | 38,460 | 961,500 | 112,622 | Apr 16 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.